300149 睿智医药
已收盘 06-12 15:00:00
资讯
新帖
简况
睿智医药：境外收入占比76.65%
证券之星 · 06-04
睿智医药：境外收入占比76.65%
睿智医药：截至2026年5月31日公司的股东人数为36,374人
证券之星 · 06-04
睿智医药：截至2026年5月31日公司的股东人数为36,374人
睿智医药（300149）披露向激励对象预留授予限制性股票公告，5月29日股价上涨3.32%
证券之星 · 05-29
睿智医药（300149）披露向激励对象预留授予限制性股票公告，5月29日股价上涨3.32%
睿智医药(300149)5月20日股东户数3.72万户，较上期减少5.04%
证券之星 · 05-26
睿智医药(300149)5月20日股东户数3.72万户，较上期减少5.04%
睿智医药：截止到2026年5月20日，公司的股东人数为37,224人
证券之星 · 05-26
睿智医药：截止到2026年5月20日，公司的股东人数为37,224人
睿智医药（300149）披露2024年度向特定对象发行股票募集说明书(申报稿)，5月20日股价下跌1.39%
证券之星 · 05-20
睿智医药（300149）披露2024年度向特定对象发行股票募集说明书(申报稿)，5月20日股价下跌1.39%
睿智医药(300149)5月10日股东户数3.92万户，较上期减少14.28%
证券之星 · 05-19
睿智医药(300149)5月10日股东户数3.92万户，较上期减少14.28%
睿智医药：截止到2026年4月30日，公司的股东人数为40,010
证券之星 · 05-19
睿智医药：截止到2026年4月30日，公司的股东人数为40,010
睿智医药：正在积极推进小分子CMC及GMP体系建设
证券之星 · 05-19
睿智医药：正在积极推进小分子CMC及GMP体系建设
睿智医药（300149）披露关于为全资子公司提供担保的进展公告，5月15日股价下跌0.94%
证券之星 · 05-15
睿智医药（300149）披露关于为全资子公司提供担保的进展公告，5月15日股价下跌0.94%
睿智医药（300149）披露2025年度网上业绩说明会安排，5月08日股价上涨0.7%
证券之星 · 05-08
睿智医药（300149）披露2025年度网上业绩说明会安排，5月08日股价上涨0.7%
股市必读：睿智医药（300149）4月30日披露最新机构调研信息
证券之星 · 05-06
股市必读：睿智医药（300149）4月30日披露最新机构调研信息
每周股票复盘：睿智医药（300149）股东户数增23.57%，一季报净利降373.36%
证券之星 · 05-03
每周股票复盘：睿智医药（300149）股东户数增23.57%，一季报净利降373.36%
睿智医药(300149)4月10日股东户数4.57万户，较上期增加23.57%
证券之星 · 04-29
睿智医药(300149)4月10日股东户数4.57万户，较上期增加23.57%
图解睿智医药一季报：第一季度单季净利润同比下降373.36%
证券之星 · 04-29
图解睿智医药一季报：第一季度单季净利润同比下降373.36%
睿智医药：公司定增项目目前仍在深交所审核过程中
证券之星 · 04-23
睿智医药：公司定增项目目前仍在深交所审核过程中
睿智医药：未聚焦单一锂系试剂连续流技术
证券之星 · 04-21
睿智医药：未聚焦单一锂系试剂连续流技术
睿智医药：参加AACR 2026年会并展示肿瘤学研究成果
证券之星 · 04-21
睿智医药：参加AACR 2026年会并展示肿瘤学研究成果
股市必读：睿智医药（300149）4月20日董秘有最新回复
证券之星 · 04-21
股市必读：睿智医药（300149）4月20日董秘有最新回复
睿智医药：截止到2026年4月10日，公司股东人数是45,729
证券之星 · 04-15
睿智医药：截止到2026年4月10日，公司股东人数是45,729
加载更多
公司概况
公司名称：
睿智医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2010-12-22
主营业务：
睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。
发行价格：
28.00
{"stockData":{"symbol":"300149","market":"SZ","secType":"STK","nameCN":"睿智医药","latestPrice":7.88,"timestamp":1781247822000,"preClose":7.68,"halted":0,"volume":8861093,"delay":0,"changeRate":0.026,"floatShares":475000000,"shares":498000000,"eps":-0.0229,"marketStatus":"已收盘","change":0.2,"latestTime":"06-12 15:00:00","open":7.81,"high":7.92,"low":7.62,"amount":69232400,"amplitude":0.0391,"askPrice":7.88,"askSize":410,"bidPrice":7.87,"bidSize":63,"shortable":0,"etf":0,"ttmEps":-0.0229,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":7.68,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":8.45,"lowLimit":6.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":497963992,"isCdr":false,"pbRate":2.98,"roa":"--","roe":"--","epsLYR":0.03,"committee":-0.140451,"marketValue":3924000000,"turnoverRate":0.0187,"status":0,"floatMarketCap":3740000000},"requestUrl":"/m/hq/s/300149","defaultTab":"news","newsList":[{"id":"2640139144","title":"睿智医药：境外收入占比76.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640139144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640139144?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:36","pubTimestamp":1780544206,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司在2025年度及2026一季度，外币占全部销售收入的比重各是多少%？睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。公司定期报告披露口径为境外收入，非外币收入口径。根据公司2025年年度报告，境外收入占比76.65%，境内收入占比23.35%。根据相关法律法规规定，对于应披露的信息，公司已按照要求在定期报告文件中进行相关列示，2026年一季度不涉及上述数据的披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640396621","title":"睿智医药：截至2026年5月31日公司的股东人数为36,374人","url":"https://stock-news.laohu8.com/highlight/detail?id=2640396621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640396621?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:30","pubTimestamp":1780543836,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年5月 31日公司的股东总数是多少？谢谢睿智医药回复：尊敬的投资者，您好，感谢对公司的关注。截至2026年5月31日公司的股东人数为36,374人。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626687","title":"睿智医药（300149）披露向激励对象预留授予限制性股票公告，5月29日股价上涨3.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626687?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:53","pubTimestamp":1780048382,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，睿智医药报收于8.72元，较前一交易日上涨3.32%，最新总市值为43.42亿元。近日，睿智医药科技股份有限公司披露《关于向激励对象预留授予限制性股票的公告》。公告显示，公司于2026年5月28日召开第六届董事会第十八次会议，确定当日为2025年限制性股票激励计划的预留授予日，向19名激励对象授予600.00万股第二类限制性股票，授予价格为3.05元/股，占公司总股本的1.20%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900033443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638590256","title":"睿智医药(300149)5月20日股东户数3.72万户，较上期减少5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638590256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638590256?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:26","pubTimestamp":1779787575,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年5月20日公司股东户数为3.72万户，较5月10日减少1977.0户，减幅为5.04%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至5月20日，医疗服务行业平均股东户数为4.86万户。从股价来看，2026年5月10日至2026年5月20日，睿智医药区间跌幅为7.96%，在此期间股东户数减少1977.0户，减幅为5.04%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600029448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665591","title":"睿智医药：截止到2026年5月20日，公司的股东人数为37,224人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665591?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:39","pubTimestamp":1779781147,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截止到5月20日股东人数是多少？谢谢睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。截止到2026年5月20日，公司的股东人数为37,224人。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600021221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636484816","title":"睿智医药（300149）披露2024年度向特定对象发行股票募集说明书(申报稿)，5月20日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636484816","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636484816?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:45","pubTimestamp":1779270319,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，睿智医药报收于9.25元，较前一交易日下跌1.39%，最新总市值为46.06亿元。近日，睿智医药科技股份有限公司披露《2024年度向特定对象发行股票募集说明书(申报稿)》。公告显示，公司拟向特定对象发行股票，发行对象为江门睿联医药投资有限公司，发行价格为5.27元/股，发行数量不超过60,019,704股，募集资金总额不超过31,630.38万元，扣除发行费用后用于补充流动资金、偿还银行借款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483438","title":"睿智医药(300149)5月10日股东户数3.92万户，较上期减少14.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483438?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:21","pubTimestamp":1779182514,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年5月10日公司股东户数为3.92万户，较4月10日减少6528.0户，减幅为14.28%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至5月10日，医疗服务行业平均股东户数为4.87万户。从股价来看，2026年4月10日至2026年5月10日，睿智医药区间跌幅为10.27%，在此期间股东户数减少6528.0户，减幅为14.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900030968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889736","title":"睿智医药：截止到2026年4月30日，公司的股东人数为40,010","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889736","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889736?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:33","pubTimestamp":1779161592,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年4月30日公司的股东总数是多少？谢谢睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。截止到2026年4月30日，公司的股东人数为40,010。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900019386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636889737","title":"睿智医药：正在积极推进小分子CMC及GMP体系建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2636889737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636889737?lang=zh_cn&edition=full","pubTime":"2026-05-19 11:33","pubTimestamp":1779161587,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在小分子CDMO上面有何规划?睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。目前公司正在积极推进小分子CMC及GMP体系建设，进一步完善从前端实验室到后端生产的全链条一站式服务能力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900019380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037707","title":"睿智医药（300149）披露关于为全资子公司提供担保的进展公告，5月15日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635037707?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:29","pubTimestamp":1778837364,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，睿智医药报收于9.44元，较前一交易日下跌0.94%，最新总市值为47.01亿元。近日，睿智医药科技股份有限公司披露《关于担保进展的公告》。本次担保在公司已审批的担保额度范围内，无需另行提交董事会或股东会审议。截至公告日，公司及控股子公司担保额度总金额为90,324.82万元，实际担保余额为8,535.81万元，占公司2025年度经审计净资产的6.69%，无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500031855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343413","title":"睿智医药（300149）披露2025年度网上业绩说明会安排，5月08日股价上涨0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633343413?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:58","pubTimestamp":1778234283,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，睿智医药报收于10.05元，较前一交易日上涨0.7%，最新总市值为50.05亿元。近日，睿智医药科技股份有限公司发布《关于举行2025年度网上业绩说明会的公告》。公告显示，公司已于2026年4月29日披露《2025年年度报告》及其摘要，为进一步加强与投资者的沟通，将于2026年5月18日15:00-17:00通过深圳证券交易所‘互动易’平台举行2025年度网上业绩说明会，采用网络远程方式召开。投资者可提前登录‘互动易’平台提交问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920005","title":"股市必读：睿智医药（300149）4月30日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633920005?lang=zh_cn&edition=full","pubTime":"2026-05-06 06:01","pubTimestamp":1778018508,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，睿智医药报收于9.99元，下跌0.1%，换手率2.56%，成交量12.16万手，成交额1.22亿元。当日关注点来自交易信息汇总：4月30日主力资金净流出243.24万元，散户资金净流入820.19万元，占总成交额6.74%。新模态业务订单中，XDC相关订单占比接近50%，其次为多肽与核酸类订单；2026年一季度小核酸业务订单呈增长趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600004155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632113670","title":"每周股票复盘：睿智医药（300149）股东户数增23.57%，一季报净利降373.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632113670","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632113670?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:04","pubTimestamp":1777763057,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，睿智医药报收于9.99元，较上周的10.57元下跌5.49%。本周，睿智医药4月28日盘中最高价报10.88元。业绩披露要点：2026年一季度归母净利润-1815.65万元，同比下降373.36%。股本股东变化股东户数变动截至2026年4月10日，公司股东户数为4.57万户，较3月31日增加8722.0户，增幅为23.57%。户均持股数量由上期的1.35万股减少至1.09万股，户均持股市值为12.2万元。2026年一季度小核酸业务订单呈增长趋势。该预案尚需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631990115","title":"睿智医药(300149)4月10日股东户数4.57万户，较上期增加23.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631990115","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631990115?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:59","pubTimestamp":1777456774,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2026年4月10日公司股东户数为4.57万户，较3月31日增加8722.0户，增幅为23.57%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至4月10日，医疗服务行业平均股东户数为4.91万户。从股价来看，2026年3月31日至2026年4月10日，睿智医药区间涨幅为8.21%，在此期间股东户数增加8722.0户，增幅为23.57%。近3个月融资净流入3181.82万，融资余额增加；融券净流出3.37万，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631369435","title":"图解睿智医药一季报：第一季度单季净利润同比下降373.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631369435","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631369435?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:30","pubTimestamp":1777408227,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药2026年一季报显示，一季度公司主营收入2.67亿元，同比上升2.08%；归母净利润-1815.65万元，同比下降373.36%；扣非净利润-1975.03万元，同比下降1157.2%；负债率35.71%，投资收益-7.15万元，财务费用790.78万元，毛利率22.15%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900009632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629834175","title":"睿智医药：公司定增项目目前仍在深交所审核过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629834175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629834175?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:51","pubTimestamp":1776948665,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)04月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司睿智的领导们减持进度如何了？是否减持满意了？另外拖了多半年的定增有消息了么？谢谢睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。关于股东的减持情况请关注公司披露的相关公告。公司定增项目目前仍在深交所审核过程中，公司将持续推动相关工作，并严格按照法律法规要求及时披露信息。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300059075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629908843","title":"睿智医药：未聚焦单一锂系试剂连续流技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2629908843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629908843?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:04","pubTimestamp":1776755057,"startTime":"0","endTime":"0","summary":"您所提及的仲丁基锂相关工艺，在公司整体研发与服务体系中应用场景有限、使用量较小。公司并未聚焦于单一锂系试剂的连续流技术，而是重点布局应用场景更广泛的微流控平台技术，目前已在小核酸药物等领域持续推进技术布局，打造差异化服务能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100029315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0216","300149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629088174","title":"睿智医药：参加AACR 2026年会并展示肿瘤学研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2629088174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629088174?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:04","pubTimestamp":1776755057,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药04月21日在投资者关系平台上答复投资者关心的问题。谢谢睿智医药回复：尊敬的投资者，您好！公司正在参加于4月17日至21日在美国圣地亚哥举行的AACR 2026年会，并设置展台，届时将进行1场口头报告及5项学术海报展示，内容涵盖公司肿瘤学研究相关成果。公司深耕CRO/CDMO领域二十余年。此次参展旨在展示公司在肿瘤药物研发领域的技术实力，并与全球生物医药创新企业开展合作交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100029312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629720044","title":"股市必读：睿智医药（300149）4月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2629720044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629720044?lang=zh_cn&edition=full","pubTime":"2026-04-21 01:44","pubTimestamp":1776707084,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，睿智医药报收于11.18元，上涨0.81%，换手率4.31%，成交量20.45万手，成交额2.27亿元。董秘最新回复投资者： 公司定增为何迟迟不获批?这样一直拖着 严重影响股价董秘： 尊敬的投资者，您好！公司定增项目目前仍在深交所审核过程中，公司将积极推动相关工作，并严格按照法律法规要求及时披露信息。当日关注点来自交易信息汇总：4月20日主力资金净流出135.35万元，游资资金净流入356.25万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100004169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627723404","title":"睿智医药：截止到2026年4月10日，公司股东人数是45,729","url":"https://stock-news.laohu8.com/highlight/detail?id=2627723404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627723404?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:18","pubTimestamp":1776241088,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止到2026年4月10日公司股东人数是多少？谢谢！睿智医药回复：尊敬的投资者，您好！感谢对公司的关注。截止到2026年4月10日，公司股东人数是45,729。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781323793607,"stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.1984},{"period":"3month","weight":-0.2229},{"period":"6month","weight":-0.1976},{"period":"1year","weight":-0.3887},{"period":"ytd","weight":-0.1757}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"睿智医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"36374人(较上一季度减少2.28%)","perCapita":"13046股","listingDate":"2010-12-22","address":"广东省江门市江海区胜利南路164号","registeredCapital":"49796万元","survey":" 睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"睿智医药,300149,睿智医药股票,睿智医药股票老虎,睿智医药股票老虎国际,睿智医药行情,睿智医药股票行情,睿智医药股价,睿智医药股市,睿智医药股票价格,睿智医药股票交易,睿智医药股票购买,睿智医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}